---
title: "European stocks \"Eleven Arhats\" | Novo Nordisk fell about 8.1%, ASML dropped over 4%"
description: "On Monday (March 10), European stocks performed poorly, with Novo Nordisk down 8.07% and ASML Holdings down 4.05%. Novo Nordisk's stock price closed at 549.40 Danish kroner, falling below the 600 mark"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/231254181.md"
published_at: "2025-03-10T17:01:09.000Z"
---

# European stocks "Eleven Arhats" | Novo Nordisk fell about 8.1%, ASML dropped over 4%

> On Monday (March 10), European stocks performed poorly, with Novo Nordisk down 8.07% and ASML Holdings down 4.05%. Novo Nordisk's stock price closed at 549.40 Danish kroner, falling below the 600 mark for the first time. SAP SE dropped 4.78%, and AstraZeneca fell 1.91%. In contrast, companies like Roche, Novartis, and Nestlé saw slight increases in their stock prices, with L'Oréal up 1.38% and GlaxoSmithKline up 1.6%

On Monday (March 10), ASML Holding's stock price in Amsterdam (ASML.NA) closed down 4.05% at €639.00. Novo Nordisk's stock price in Copenhagen (NOVOB.DC) closed down 8.07% at 549.40 Danish Krone, marking the first time since August 7, 2023, that it closed below the psychological level of 600 (closing at 545.70 that day). SAP in Germany fell 4.78%, AstraZeneca dropped 1.91%, and LVMH and Sanofi fell by up to 0.69%. Roche, Novartis, and Nestlé rose by up to 0.87%, L'Oréal increased by 1.38%, and GlaxoSmithKline rose by 1.6%

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)
- [ASML.US - ASML](https://longbridge.com/en/quote/ASML.US.md)
- [GSK.US - GSK](https://longbridge.com/en/quote/GSK.US.md)
- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)
- [SAP.US - SAP AG-Sponsored](https://longbridge.com/en/quote/SAP.US.md)
- [LRLCY.US - L'Oréal S.A.](https://longbridge.com/en/quote/LRLCY.US.md)
- [NSRGY.US - Nestlé](https://longbridge.com/en/quote/NSRGY.US.md)
- [NSRGF.US - Nestlé S.A.](https://longbridge.com/en/quote/NSRGF.US.md)
- [NVS.US - NOVARTIS AG](https://longbridge.com/en/quote/NVS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Novo Nordisk A/S - share repurchase programme | Novo Nordisk A/S has initiated a share repurchase programme of up to DKK 15 billion, starting from 4 February 2026. As o | [Link](https://longbridge.com/en/news/276056741.md) |
| Novo Nordisk Proposes Two Additional New Board Appointments | Danish pharmaceutical company Novo Nordisk is proposing three new appointments to its board of directors for the annual  | [Link](https://longbridge.com/en/news/276442777.md) |
| Puzo Michael J Has $320,000 Stock Position in Novo Nordisk A/S $NVO | Puzo Michael J significantly reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 86.9% in Q3, now holding 5,775 shares v | [Link](https://longbridge.com/en/news/276447697.md) |
| Novo Nordisk: Will Have Replacements for Ozempic and Wegovy Ready When Patents Expire - Berlingske | Danish pharmaceutical company Novo Nordisk plans to have replacement drugs ready for Ozempic and Wegovy when their paten | [Link](https://longbridge.com/en/news/276314777.md) |
| GLP-1 Anti-Obesity U.S. Drug Market In Four Charts | UBS analysts, led by Matthew Weston, have analyzed trends in the U.S. GLP-1 anti-obesity drug market, focusing on new-to | [Link](https://longbridge.com/en/news/276280378.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.